Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has won a legal victory in the US worth about $500 million to the company. By a majority of five to four, the US Supreme Court has ruled that generic drug companies cannot be sued under state law over allegations that they failed to provide adequate label warnings about potential side effects. (Globes)
You must be Logged in to post comment.
